Roche, AstraZeneca follow Merck's lead with large RNAi investments

Roche and AstraZeneca have followed Merck's lead in investing heavily in the relatively new field of RNA interference gene-silencing treatments. Roche signed with Alnylam Pharmaceuticals, a biotech with expertise in RNA interference treatments, in a licensing deal that could reach $1 billion, while AstraZeneca signed a smaller deal with the U.K.'s Silence Therapeutics, worth just over $400 million. Earlier, Merck obtained its access to RNAi by buying Sirna Therapeutics for $1.1 billion.

View Full Article in:

International Herald Tribune · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR